1. Genentech's subcutaneous Ocrevus shows near-complete suppression of relapses (97%) and brain lesions (97.2%) in MS patients after one year in a Phase III study.

Genentech's subcutaneous Ocrevus shows near-complete suppression of relapses (97%) and brain lesions (97.2%) in progressive and relapsing MS patients after one year in a Phase III study. The twice-yearly, 10-minute injection has potential for wider use in centers without IV facilities or capacity limitations. FDA and EMA accept filings based on OCARINA II data, with EU approval expected mid-2024 and U.S. approval in September 2024.